CAR T cancer biotech CARGO Therapeutics targets a $300 million IPO

 Another large biotech IPO has joined the calendar, seeking to buck the trend of mostly negative returns from recent listings in the industry.

CARGO Therapeutics (CRGX) launched on Monday, planning to raise $300 million in what would be the year's fourth-largest biotech IPO to date. Its proposed deal size would put it in the largest 5% of biotech IPOs in the past decade. 

https://www.renaissancecapital.com/IPO-Center/News/101751/CAR-T-cancer-biotech-CARGO-Therapeutics-targets-a-$300-million-IPO-as-it-se